Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 11041 - 11048 of 12141 results
Fifth Circuit Joins Chorus to Rein in False Claims Act
August 27, 2013| Blog| Viewpoint
California “Do Not Track” Bill Stays on Track
August 27, 2013| Blog| Viewpoint
Privacy Monday - August 26, 2013
August 26, 2013| Blog| Viewpoint
No CPSC Enforcement Can be Admissible Evidence in a Products Liability Case
August 24, 2013| Blog| Viewpoint
FTC & Green Advertising: Mattress Companies Settle FTC Allegations of Unsubstantiated “VOC” Marketing Claims
August 22, 2013| Blog| Viewpoint
Oops! Assignment of Intent-to-Use Trademark Applications: Easy But Not Simple
August 22, 2013| Blog| Viewpoint
You Can Have a Say on a New Mechanism for Obtaining Verifiable Parental Consent under the COPPA Rule
August 22, 2013| Blog| Viewpoint
Government Prosecution in Qui Tam Cases Continues to Focus on Pharmaceutical Companies’ Sales and Marketing Activities
August 21, 2013| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts
Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|